Argus Increases HCA Healthcare (HCA) Price Target to $155.00

HCA Healthcare (NYSE:HCA) had its target price increased by research analysts at Argus from $150.00 to $155.00 in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. Argus’ price target suggests a potential upside of 9.42% from the company’s previous close.

A number of other research firms also recently weighed in on HCA. SunTrust Banks upped their target price on shares of HCA Healthcare to $150.00 and gave the stock a “positive” rating in a research report on Tuesday, September 4th. Credit Suisse Group upped their target price on shares of HCA Healthcare from $156.00 to $165.00 and gave the stock an “outperform” rating in a research report on Thursday, November 1st. Citigroup upped their target price on shares of HCA Healthcare from $136.00 to $156.00 and gave the stock a “buy” rating in a research report on Thursday, October 11th. Jefferies Financial Group upped their target price on shares of HCA Healthcare from $155.00 to $158.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Finally, Mizuho set a $150.00 target price on shares of HCA Healthcare and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $141.53.

NYSE:HCA opened at $141.65 on Tuesday. The stock has a market capitalization of $46.80 billion, a PE ratio of 21.49, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. HCA Healthcare has a 1-year low of $74.26 and a 1-year high of $141.89.

HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, October 30th. The company reported $2.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.93 by $0.23. The firm had revenue of $11.45 billion for the quarter, compared to the consensus estimate of $11.29 billion. HCA Healthcare had a net margin of 6.82% and a negative return on equity of 73.71%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.13 EPS. As a group, research analysts anticipate that HCA Healthcare will post 9.35 earnings per share for the current fiscal year.

In other HCA Healthcare news, SVP Deborah M. Reiner sold 723 shares of the company’s stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $135.06, for a total transaction of $97,648.38. Following the transaction, the senior vice president now owns 6,184 shares in the company, valued at approximately $835,211.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jane D. Englebright sold 6,543 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $129.86, for a total transaction of $849,673.98. Following the transaction, the senior vice president now owns 7,443 shares in the company, valued at approximately $966,547.98. The disclosure for this sale can be found here. Insiders have sold a total of 12,462 shares of company stock worth $1,656,680 over the last three months. 2.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of HCA. DnB Asset Management AS lifted its stake in HCA Healthcare by 5.6% during the 2nd quarter. DnB Asset Management AS now owns 35,944 shares of the company’s stock valued at $3,688,000 after acquiring an additional 1,900 shares during the period. IFM Investors Pty Ltd lifted its stake in HCA Healthcare by 44.1% during the 2nd quarter. IFM Investors Pty Ltd now owns 12,531 shares of the company’s stock valued at $1,286,000 after acquiring an additional 3,834 shares during the period. State of Alaska Department of Revenue lifted its stake in HCA Healthcare by 27.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 45,700 shares of the company’s stock valued at $4,687,000 after acquiring an additional 9,910 shares during the period. Confluence Investment Management LLC bought a new position in HCA Healthcare during the 2nd quarter valued at about $283,000. Finally, NN Investment Partners Holdings N.V. lifted its stake in HCA Healthcare by 198.9% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 170,204 shares of the company’s stock valued at $17,463,000 after acquiring an additional 113,265 shares during the period. Institutional investors and hedge funds own 70.84% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Read More: What is Cost of Debt?

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply